Dergiler / Turkish Journal of Gastroenterology / 2022 / Cilt: 33 - Sayı: 6

Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis

Sayfa
497–504
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, more welldesigned studies focusing on proton pump inhibitor use and the risk of diabetes mellitus, especially among populations with different backgrounds, are still needed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Proton pump inhibitor use was reported to potentially provide benefits to prevent diabetes mellitus.
📊
Temel Bulgular & Veri:Methods: This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42021238481).
💡
Sonuç & Katkı:However, more welldesigned studies focusing on proton pump inhibitor use and the risk of diabetes mellitus, especially among populations with different backgrounds, are still needed.
🔬Tür:Laboratuvar & Saha Deneyi
📍Kapsam:2021 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Proton pump inhibitor use was reported to potentially provide benefits to prevent diabetes mellitus. This study aims to investigate the association between proton pump inhibitor use and the risk of developing diabetes mellitus. Methods: This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42021238481). A systematic literature search was conducted to identify eligible studies up to February 2021. Quality assessment was conducted according to Jadad Scoring Scale and Newcastle–Ottawa Scale. The heterogeneity among studies was tested and estimated by Q test and I2. Pooled hazard ratio with 95% CI was calculated using the random-effects or fixed-effects model depending on the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also performed. Results: Eight studies including 850 019 participants were included. We found that proton pump inhibitor use was associated with a statistically non-significant increased risk of diabetes mellitus (pooled hazard ratio was 1.06, 95% CI = 0.89-1.28, P = .50). In subgroup analysis, 5 studies conducted in North America confirmed the overall result; however, one study conducted in Europe demonstrated a statistically significant increased risk, while one study in Asia revealed a statistically significant decreased risk. Conclusion: Proton pump inhibitor use is not associated with either increased or decreased risk of diabetes mellitus. However, more welldesigned studies focusing on proton pump inhibitor use and the risk of diabetes mellitus, especially among populations with different backgrounds, are still needed.

🔖

Bu Makaleye Atıf Yap

CHEN, Y., HU, L., SUN, C., BAO, J., LIU, J., BHAN, C., KIM, K. Y., MANEM, R., THAPA, P., MA, S., LIU, M., CHENG, X., CHENG, C., ZHOU, Q. (2022). Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis. Turkish Journal of Gastroenterology, Cilt: 33 - Sayı: 6, 497–504. https://ajindex.com/articles/417304

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Petersmann A, Müller-Wieland D, Müller UA, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2019
  2. S1-S7. [CrossRef] 2. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012
  3. [CrossRef] 3. Burillo J, Fernández-Rhodes M, Piquero M, et al. Human amylin aggregates release within exosomes as a protective mechanism in pancreatic β cells: pancreatic β-hippocampal cell communication. Biochim Biophys Acta Mol Cell Res. 2021
  4. 1868(5):118971. [CrossRef] 4. Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 2002
  5. 51(3):686- 690. [CrossRef] 5. Suarez-Pinzon WL, Lakey JRT, Brand SJ, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. J Clin Endocrinol Metab. 2005
  6. 90(6):3401-3409. [CrossRef] 6. Song I, Patel O, Himpe E, Muller CJF, Bouwens L. Beta cell mass restoration in alloxan-diabetic mice treated with EGF and gastrin. PLoS One. 2015
  7. 10(10):e0140148. [CrossRef] 7. Téllez N, Joanny G, Escoriza J, Vilaseca M, Montanya E. Gastrin treatment stimulates β-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats. Endocrinology. 2011
  8. 152(7):2580-2588. [CrossRef] 8. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs. 2013
  9. 15(2):119-131. [CrossRef] 9. Shin JM, Sachs G. Long-lasting inhibitors of the gastric H,KATPase. Expert Rev Clin Pharmacol. 2009
  10. 2(5):461-468. [CrossRef] 10. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008
  11. 134(7):1842-1860. [CrossRef] 11. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021
  12. 70(6):1070-1077. [CrossRef] 12. Lin HC, Hsiao YT, Lin HL, et al. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: a population-based retrospective cohort study. Med. 2016
  13. 95(28):e4195. [CrossRef] 13. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving Rivaroxaban or aspirin